Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Name: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Published: 2020
License: Public Domain

Prevail Therapeutics · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

frontotemporaldementia genetherapy

frontotemporal dementia, fronto-temporal dementia, progranulin mutations, ftd-grn, gene therapy, dementia gene therapy, aav9, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Related documents